Parental Subsidies for Diagnostics
Executive SummaryWrapped in a modish genomic gown, in vitro diagnostics are back in fashion. No sooner has Applera (formerly PE Corp.) announced a major new initiative in diagnostics than diaDexus files for an IPO. But these aren't your grandfather's diagnostics companies: they start life with huge pharmaceutical subsidies in terms of genomic data and financing.
You may also be interested in...
CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.